158 related articles for article (PubMed ID: 34117720)
1. The Immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells.
Perini T; Materozzi M; Milan E
FEBS J; 2022 Aug; 289(15):4383-4397. PubMed ID: 34117720
[TBL] [Abstract][Full Text] [Related]
2. Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis.
Tang TF; Chan YT; Cheong HC; Cheok YY; Anuar NA; Looi CY; Gan GG; Wong WF
Cell Immunol; 2022 Oct; 380():104594. PubMed ID: 36081178
[TBL] [Abstract][Full Text] [Related]
3. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
Agnarelli A; Chevassut T; Mancini EJ
Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
[TBL] [Abstract][Full Text] [Related]
4. The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis.
Fucci C; Resnati M; Riva E; Perini T; Ruggieri E; Orfanelli U; Paradiso F; Cremasco F; Raimondi A; Pasqualetto E; Nuvolone M; Rampoldi L; Cenci S; Milan E
Cell Rep; 2020 Sep; 32(12):108162. PubMed ID: 32966780
[TBL] [Abstract][Full Text] [Related]
5. Loss of
Zhu YX; Shi CX; Bruins LA; Jedlowski P; Wang X; Kortüm KM; Luo M; Ahmann JM; Braggio E; Stewart AK
Cancer Res; 2017 Aug; 77(16):4317-4327. PubMed ID: 28619709
[No Abstract] [Full Text] [Related]
6. IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis.
Low MSY; Brodie EJ; Fedele PL; Liao Y; Grigoriadis G; Strasser A; Kallies A; Willis SN; Tellier J; Shi W; Gabriel S; O'Donnell K; Pitt C; Nutt SL; Tarlinton D
Cell Rep; 2019 Nov; 29(9):2634-2645.e5. PubMed ID: 31775034
[TBL] [Abstract][Full Text] [Related]
7. IRF4 addiction in multiple myeloma.
Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
[TBL] [Abstract][Full Text] [Related]
8. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
9. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma.
Mroczek S; Chlebowska J; Kuliński TM; Gewartowska O; Gruchota J; Cysewski D; Liudkovska V; Borsuk E; Nowis D; Dziembowski A
Nat Commun; 2017 Sep; 8(1):619. PubMed ID: 28931820
[TBL] [Abstract][Full Text] [Related]
10. FAM46C and FNDC3A Are Multiple Myeloma Tumor Suppressors That Act in Concert to Impair Clearing of Protein Aggregates and Autophagy.
Manfrini N; Mancino M; Miluzio A; Oliveto S; Balestra M; Calamita P; Alfieri R; Rossi RL; Sassoè-Pognetto M; Salio C; Cuomo A; Bonaldi T; Manfredi M; Marengo E; Ranzato E; Martinotti S; Cittaro D; Tonon G; Biffo S
Cancer Res; 2020 Nov; 80(21):4693-4706. PubMed ID: 32963011
[TBL] [Abstract][Full Text] [Related]
11. FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma.
Herrero AB; Quwaider D; Corchete LA; Mateos MV; García-Sanz R; Gutiérrez NC
J Cell Mol Med; 2020 Apr; 24(7):4171-4182. PubMed ID: 32141701
[TBL] [Abstract][Full Text] [Related]
12. Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.
Alvarez-Benayas J; Trasanidis N; Katsarou A; Ponnusamy K; Chaidos A; May PC; Xiao X; Bua M; Atta M; Roberts IAG; Auner HW; Hatjiharissi E; Papaioannou M; Caputo VS; Sudbery IM; Karadimitris A
Nat Commun; 2021 Sep; 12(1):5450. PubMed ID: 34521827
[TBL] [Abstract][Full Text] [Related]
13. Unfolded protein response inducers tunicamycin and dithiothreitol promote myeloma cell differentiation mediated by XBP-1.
Jiang H; Zou J; Zhang H; Fu W; Zeng T; Huang H; Zhou F; Hou J
Clin Exp Med; 2015 Feb; 15(1):85-96. PubMed ID: 24356728
[TBL] [Abstract][Full Text] [Related]
14. Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.
Auner HW; Cenci S
Br J Haematol; 2015 Jan; 168(1):14-25. PubMed ID: 25296649
[TBL] [Abstract][Full Text] [Related]
15. High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma.
Chhabra S; Jain S; Wallace C; Hong F; Liu B
J Hematol Oncol; 2015 Jun; 8():77. PubMed ID: 26108343
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
Ikeda S; Kitadate A; Abe F; Saitoh H; Michishita Y; Hatano Y; Kawabata Y; Kitabayashi A; Teshima K; Kume M; Takahashi N; Tagawa H
Cancer Sci; 2017 Apr; 108(4):641-652. PubMed ID: 28164410
[TBL] [Abstract][Full Text] [Related]
17. Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells.
Kanasugi J; Hanamura I; Ota A; Karnan S; Lam VQ; Mizuno S; Wahiduzzaman M; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Takami A
Cancer Sci; 2020 May; 111(5):1663-1675. PubMed ID: 32176823
[TBL] [Abstract][Full Text] [Related]
18. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization.
Jourdan M; Caraux A; De Vos J; Fiol G; Larroque M; Cognot C; Bret C; Duperray C; Hose D; Klein B
Blood; 2009 Dec; 114(25):5173-81. PubMed ID: 19846886
[TBL] [Abstract][Full Text] [Related]
19. HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.
Vandyke K; Zeissig MN; Hewett DR; Martin SK; Mrozik KM; Cheong CM; Diamond P; To LB; Gronthos S; Peet DJ; Croucher PI; Zannettino ACW
Cancer Res; 2017 Oct; 77(20):5452-5463. PubMed ID: 28855206
[TBL] [Abstract][Full Text] [Related]
20. Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells.
Catena V; Bruno T; De Nicola F; Goeman F; Pallocca M; Iezzi S; Sorino C; Cigliana G; Floridi A; Blandino G; Fanciulli M
Oncotarget; 2016 Oct; 7(43):70546-70558. PubMed ID: 27655709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
